Acetylon Pharmaceuticals, Inc.
Records under this name other than the patents Acetylon Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 21 patents it holds.
Back to Acetylon Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,145,412 | Selective HDAC1 and HDAC2 inhibitors Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,096,549 | Selective HDAC3 inhibitors Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,139,583 | Selective HDAC3 inhibitors Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,125,131 | Selective HDAC3 inhibitors Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,239,837 | Piperidine Derivatives as HDAC1/2 Inhibitors Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 10,358,421 | Piperidine Derivatives as HDAC1/2 Inhibitors Formerly held In force · High confidence | In force | High confidence | |
| US 11,702,389 | Piperidine Derivatives as HDAC1/2 Inhibitors Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 10,272,084 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Cisplatin-Induced Peripheral Neuropathy Formerly held In force · High confidence | In force | High confidence | |
| US 11,813,261 | Hdac Inhibitors, Alone or in Combination with BTK Inhibitors, for Treating Chronic Lymphocytic Leukemia Formerly held In force · High confidence | In force | High confidence | |
| US 10,040,769 | Hdac Inhibitors for the Treatment of Diabetic Peripheral Neuropathy Lapsed on the fee record Ended Aug 7, 2026 · High confidence | Lapsed on the fee record | Ended Aug 7, 2026 | High confidence |